enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Regeneron Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Regeneron_Pharmaceuticals

   Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...

3. Biotech company Regeneron buys Avon site in Rockland ... - AOL

   www.aol.com/biotech-company-regeneron-buys-avon...

   Regeneron will also get a tax break on about $50 million of the renovation costs at the site, with exemptions of up to about $4.19 million in state and local sales taxes, according to IDA documents.

4. US FDA declines to approve Regeneron's higher-dose Eylea ...

   www.aol.com/news/us-fda-declines-approve...

   Regeneron's shares closed down 8.6% at $715.9. The U.S. Food and Drug Administration issued a complete response letter, indicating the agency has review US FDA declines to approve Regeneron's ...

5. US FDA declines to approve Regeneron's blood cancer therapy - AOL

   www.aol.com/news/us-fda-declines-approve...

   Regeneron said in early August that the FDA's concerns about a third-party manufacturer will cause a delay in the regulatory decision for linvoseltamab, even though the issues were resolved and ...

6. Regeneron to collaborate on gene editing therapies with ...

   www.aol.com/news/regeneron-collaborate-gene...

   Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR ...

7. Regeneron's Eylea could return to growth after nod to high ...

   www.aol.com/news/regenerons-eylea-could-return...

   Shares of Regeneron rose 1.7% to $826.4 in early trading. A longer dosing gap for the drug could help Regeneron take on rival Roche's Vabysmo and also help soften the blow from incoming cheaper ...

8. Regeneron's blood cancer therapy faces setback as FDA ... - AOL

   www.aol.com/news/regenerons-blood-cancer-therapy...

   Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo

9. Regeneron beats quarterly results on strong demand for ... - AOL

   www.aol.com/news/regeneron-beats-quarterly...

   Regeneron reported an adjusted profit of $11.56 per share on total revenue of $3.55 billion for the quarter, above analysts' estimates of $10.61 per share and $3.38 billion, according to LSEG data.